Serzone: Black Box to Jury Box?

photo-1In the months following the decision of the U.S. Food and Drug Administration and Bristol-Myers Squibb Co., to include a Black Box warning with Serzone (nefazodone) to advise patients that the drug has been associated with liver damage that may require a liver transplant, the products liability litigation involving the antidepressant's manufacturer has grown by leaps and bounds. photo-2 The plaintiffs, who have allegedly suffered liver damage or liver necrosis, are pursuing claims against Bristol-Myers Squibb that assert allegations under theories of strict liability including failure to warn and defective product design, negligence and breach of express and implied …